• Champions Oncology posted Q4 revenue of $13.8 million, up 12% from a year earlier, as GAAP net loss narrowed to $667,000.
• GAAP operating loss tightened to $522,000; non-GAAP adjusted EBITDA swung to income of $158,000.
• Oncology services margin widened 10 percentage points to 51%, on lower outsourced research services costs and continued radiopharmaceutical work brought in-house.
• For fiscal 2026, revenue rose 4% to $59.4 million, while GAAP net results turned to a $1.18 million loss.
• Management cited continued investment in radiopharmaceuticals, the data platform, and commercial expansion, with adjusted EBITDA positive in all four quarters.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607271600ACCESSWRNAPR_____1196729) on July 27, 2026, and is solely responsible for the information contained therein.